Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rissmann

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Clinical and Translational Science|April 22, 2020
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II TrialTessa Niemeyer-van der Kolk, Hein van der Wall, Geretta K Hogendoorn, et al.
British Journal of Clinical Pharmacology|May 11, 2026
Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trialLaura W J van der Meulen, Menthe E Bergmans, Salma Assil, et al.
Journal of the American Academy of Dermatology|October 7, 2023
Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trialJannik Rousel, Menthe E Bergmans, Laura W J van der Meulen, et al.
JMIR Medical Informatics|October 10, 2025
Evaluation of Machine Learning Model Performance in Diabetic Foot Ulcer: Retrospective Cohort StudyVeerle Y van Velze, Hendrico L Burger, Tim J van der Steenhoven, et al.
Acta Dermato-Venereologica|November 20, 2019
Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic DermatitisEllen H A van den Munckhof, Tessa Niemeyer-van der Kolk, Hein van der Wall, et al.
Journal of the American Academy of Dermatology|October 3, 2020
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trialTessa Niemeyer-van der Kolk, Thomas P Buters, Lara Krouwels, et al.
British Journal of Clinical Pharmacology|July 22, 2021
Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteersThomas P Buters, Pieter W Hameeteman, Iris M E Jansen, et al.
Cancers|March 25, 2022
Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled TrialSelinde S Wind, Manon A A Jansen, Melanie Rijsbergen, et al.
British Journal of Clinical Pharmacology|January 6, 2021
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trialJustin Jacobse, Wouter Ten Voorde, Anushka Tandon, et al.
Cancers|March 11, 2023
Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. <i>Cancers</i> 2022, <i>14</i>, 1510Selinde S Wind, Manon A A Jansen, Melanie Rijsbergen, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Clinical and Translational Science|April 22, 2020
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II TrialTessa Niemeyer-van der Kolk, Hein van der Wall, Geretta K Hogendoorn, et al.
British Journal of Clinical Pharmacology|May 11, 2026
Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trialLaura W J van der Meulen, Menthe E Bergmans, Salma Assil, et al.
Journal of the American Academy of Dermatology|October 7, 2023
Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trialJannik Rousel, Menthe E Bergmans, Laura W J van der Meulen, et al.
JMIR Medical Informatics|October 10, 2025
Evaluation of Machine Learning Model Performance in Diabetic Foot Ulcer: Retrospective Cohort StudyVeerle Y van Velze, Hendrico L Burger, Tim J van der Steenhoven, et al.
Acta Dermato-Venereologica|November 20, 2019
Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic DermatitisEllen H A van den Munckhof, Tessa Niemeyer-van der Kolk, Hein van der Wall, et al.
Journal of the American Academy of Dermatology|October 3, 2020
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trialTessa Niemeyer-van der Kolk, Thomas P Buters, Lara Krouwels, et al.
British Journal of Clinical Pharmacology|July 22, 2021
Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteersThomas P Buters, Pieter W Hameeteman, Iris M E Jansen, et al.
Cancers|March 25, 2022
Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled TrialSelinde S Wind, Manon A A Jansen, Melanie Rijsbergen, et al.
British Journal of Clinical Pharmacology|January 6, 2021
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trialJustin Jacobse, Wouter Ten Voorde, Anushka Tandon, et al.
Cancers|March 11, 2023
Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. <i>Cancers</i> 2022, <i>14</i>, 1510Selinde S Wind, Manon A A Jansen, Melanie Rijsbergen, et al.
Pageof 10